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Virus controllersCD8+ T-lymphocytes fromHIV-1 infected individuals express unidentiﬁed factors that suppress viral replication
by inhibiting HIV-1 gene expression. We examined the role of epigenetics in modulating the HIV-1 suppressive
factors expressedbyprimary CD8+T cells fromsubjects naturally controlling virus replication. HIV-1 suppression
by CD8+ T-lymphocytes was reversed up to 40% by the addition of a histone deacetylase (HDAC) inhibitor.
Noncytolytic suppression was not dependent on epigenetic changes within the target cells, as HDAC1within the
target cell was dispensable, and HIV-1 LTR histone acetylation remained unchanged in the presence of CD8+ T-
lymphocytes. Histone deacetylation within CD8+ T-lymphocytes was necessary for potent HIV-1 suppression.
Blocking HDACs impairs the ability of CD8+ T-lymphocytes to repress HIV-1 transcription, demonstrating that
expression of a portion of the suppressive factors is regulated by epigenetics. These data provide a way to focus
the search for the suppressive factors and to potentially modulate their expression.earch Drive, Duke University
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Understanding the antiviral immune responses that mediate potent
suppression of HIV-1 infection would aid in designing vaccines and
therapies. A subset of asymptomatic, antiretroviral-naïve patients have
been termed controllers with the common characteristics of sustained
control of virus load and HIV-1-speciﬁc immunity (Lambotte et al.,
2005). Controllers are divided into several different groups based on
viral load in the absence of drug therapy (Grabar et al., 2009; Walker,
2007). Virus controllers have higher viral loads than elite controllers
(Walker, 2007), but maintain viral loads lower than progressing HIV-1-
infected individuals (Addo et al., 2007). The immune responses of
controllers are intensely studied to elucidate the types of responses that
could be elicited with a vaccine to mediate control of HIV-1 infection.
CD8+ T-lymphocytes can inhibit HIV-1 replication by cytolytic and
noncytolytic responses (Walker et al., 1987, 1986). The noncytolytic
response is characterized by suppression of HIV-1 replication without
lysis of the infected cell (Walker et al., 1991). A subset of CD8+ T-
lymphocytes exhibits noncytolytic suppression without detectablecytolytic activity, distinguishing these two types of antiviral activity
(Toso et al., 1995). For CCR5-tropic viruses, noncytolytic suppression
can be mediated by MIP-1α, MIP-1β, and RANTES (Cocchi et al., 1995).
However, the factors responsible for suppression of CXCR4-tropic
viruses are still unknown. Noncytolytic suppression of CXCR4-tropic
viruses can bemediated by inhibition of HIV-1 gene expression (Chenet
al., 1993; Tomaras et al., 2000), with effects more speciﬁcally on
transcription initiation (Overman et al., 2007). Themolecules that result
in suppression of HIV-1 transcription are still unknown, which has
impeded the determination of the mechanism of noncytolytic suppres-
sion. Noncytolytic suppression can occur when CD8+ T-lymphocytes
and HIV-1 infected cells are separated by a semi-permeable membrane,
however the most potent suppression occurs with direct contact even
between cells with mismatched MHC alleles (Walker and Levy, 1989).
The lack of necessity for cell contact suggests that the some portion of
the noncytolytic response is comprised of soluble factors (Walker and
Levy, 1989). Themagnitudeof thenoncytolytic response correlateswith
clinical status of HIV-1 infection; with asymptomatic individuals
exerting the strongest noncytolytic suppression (Mackewicz et al.,
1991) and with a preservation of the CD8 response in HIV+ subjects on
early HAART (Chun et al., 2001). However, there is an unexplained
variation in the presence of the noncytolytic response among HIV-
infected individuals (Walker et al., 1989).Understandingwhat regulates
this response may provide insight into how to induce a potent
noncytolytic response in all HIV-1 infected individuals.
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(Jenuwein and Allis, 2001). The structure of chromatin can be altered
to up-regulate or down-regulate the expression of genes encoded by
the DNA (Jenuwein and Allis, 2001). The “histone code” contends that
the structure of the chromatin is governed by post-translational
modiﬁcations of the histone proteins to alter gene expression (Turner,
1993). In particular, acetylation of the lysine residues on N-terminal
tails of the histones leads to less dense chromatin permissive for
transcription (Hebbes et al., 1992). Furthermore, acetylated histone
tails act as binding sites for “effector”molecules that inﬂuence higher-
order chromatin structure and RNA polymerase recruitment
(reviewed in Ruthenburg et al., 2007). Removing the acetyl groups
from the histone tails compacts the chromatin and removes the
binding sites of positive transcription regulators resulting in repressed
transcription of the associated DNA (Hebbes et al., 1992; Turner,
2000). The acetyl groups are removed from the histone tails by a
group of enzymes called histone deacetylases (HDACs) (Taunton
et al., 1996). The epilepsy drug, valproic acid (VPA) is a common small
molecule used to inhibit histone deacetylases (Gottlicher et al., 2001).
VPA has been shown to inhibit the activity of all of the class I and II
HDACs tested except HDAC10 (Catalano et al., 2007; Gottlicher et al.,
2001; Gurvich et al., 2004). By increasing acetylation of histones VPA
can alter the transcription proﬁle of cells. Using various techniques
and cell types, investigators have shown that histone deacetylation
regulates the expression of 2–9% of human genes (Agarwal et al.,
2009; Van Lint et al., 1996b). Histone acetylation also regulates HIV-1
transcription (Coull et al., 2000; Van Lint et al., 1996a). Optimal HIV-1
transcription is associated with acetylation of the histones associated
with the HIV-1 long terminal repeat (LTR) (Lusic et al., 2003).
Furthermore, HDAC1 is recruited to the HIV-1 LTR to repress
transcription from latent provirus (Tyagi and Karn, 2007; Williams
et al., 2006; Ylisastigui et al., 2004). Thus, epigenetics could modulate
HIV-1 infection by altering gene expression in effector T cells or by
directly inﬂuencing HIV-1 transcription in infected cells.
In this studywe assessed the role of epigenetics in the noncytolytic
response. We investigated the importance of histone deacetylation in
the expression of antiviral factors from CD8+ T-lymphocytes, and its
importance for directly inhibiting HIV-1 transcription by noncytolytic
suppression. We found that a subset of the genes encoding antiviral
factors from CD8+ T-lymphocytes from select virus controllers was
regulated by HDACs.
Results
Inhibition of histone deacetylation during noncytolytic suppression
increases HIV-1 replication
Previous studies demonstrated that noncytolytic suppression acts
on HIV-1 transcription and gene expression (Chen et al., 1993;
Mackewicz et al., 1995; Tomaras et al., 2000), with speciﬁc effects on
transcription initiation (Overman et al., 2007). We modeled non-
cytolytic suppression in vitro using JR-HVS CD8+ T-lymphocytes. JR-
HVS CD8+ T-lymphocytes inhibit HIV-1 transcription initiation
(Overman et al., 2007), without any cytotoxic effects (Lacey et al.,
1998). Therefore, the CD8+ T-lymphocyte cell line, JR-HVS, possesses
consistent noncytolytic antiviral activity making these cells a valid
resource for determining the mechanism of noncytolytic suppression.
First, we examined the ability of valproic acid to inhibit histone
deacetylation in CD4+ T-lymphocytes from a pool of 10 seronegative
donors, an individual seronegative donor, and primary T-lymphocytes
from an HIV-1+ virus controller. JR-HVS CD8+ T-lymphocytes were
also cultured with valproic acid to determine if valproic acid inhibited
histone deacetylation in CD8+ T-lymphocytes. Baseline levels of
acetylated histone 3 (H3ac) in CD4+ T-lymphocytes are shown in
Fig. 1A. Valproic acid stimulated acetylation of histones (H3ac),
without altering the levels of total histone 3 (H3), in CD4+ and CD8+T-lymphocytes (Fig. 1A). Thus, valproic acid altered the amount of
H3ac speciﬁcally, and not overall expression of H3. Taken together,
the effects of valproic acid on CD4+ T cells and JR-HVS CD8+ T-
lymphocytes provide a model for exploration of the effect of histone
acetylation on noncytolytic suppression in vitro.
It is unknown if alteration of chromatin structure, through histone
deacetylation, can regulate expression of the genes responsible for
noncytolytic suppression of HIV-1 transcription. To examine this, we
determined if inhibition ofHDACby valproic acid could reverse CD8+T
cell mediated virus suppression (Fig. 1B). Valproic acid stimulation
increased virus replication in a dose-dependent manner. At 1.0 mM,
replication in the CD8+ T cell co-culture signiﬁcantly increased 3.7-
fold to 63% of the replication control (pb0.001). In contrast, HIV
replication in CD4+ lymphocytes in the presence of seronegative CD8+
T-lymphocytes was unresponsive to HDAC inhibition (Fig. 1B). These
data demonstrate that alterations in chromatin, through histone
deacetylation, were required for optimal and speciﬁc CD8+ T cell
mediated virus suppression.
Dose-dependent CD8+ T cell mediated virus suppression requires
histone deacetylation
To determine if the requirement of histone deacetylation was
dependent on a speciﬁc concentrations of CD8+ effector cells, CD8+ T-
lymphocytes were examined at a series of effector: target (E:T) cell
ratios. HIV-1 replication in the CD8+ T cell co-cultures decreased from
51.6% at the lowest concentration (0.5:1, E:T) down to 9.6% at the
highest concentration (2:1, E:T), demonstrating a CD8+ T-lymphocyte
concentration-dependent response (Fig. 1C). Valproic acid stimula-
tion signiﬁcantly increased virus replication to 86.7% and 37.5% at
0.5:1 and 2:1 (E:T) ratios compared to control infection respectively
(pb0.01 and pb0.05 respectively; Fig. 1C). Inhibition of histone
deacetylation reduced noncytolytic suppression by an average 30% at
all three E:T ratios. The addition of valproic acid in the growth media
increased the EC50 more than three-fold from an E:T ratio of 0.5:1
without VPA to 1.6:1 with VPA (Fig. 1C). Thus, the inhibition of HDACs
led to a consistent reduction in noncytolytic suppression irrespective
of effector to target ratios.
Histone deacetylation is required for soluble noncytolytic suppression
We speciﬁcally studied only the soluble portion of virus suppres-
sion and the contribution of epigenetically regulated genes to the
non-contact required portion of suppression by separating the CD8+
and CD4+ T-lymphocytes by a semi-permeable membrane (transwell
cultures). Soluble factors from CD8+ T-lymphocytes suppressed HIV-
1 replication in CD4+ T-lymphocytes by 34% (Fig. 1D). Similar to the
effect that was observed in the direct contact co-culture system,
valproic acid showed a dose-dependent reversion of soluble non-
cytolytic suppression. HIV-1 replication signiﬁcantly increased after
stimulation with 0.75 and 1.25 mM valproic acid (pb0.05 for both;
Fig. 1D). Thus, hyperacetylation inhibited both soluble and contact-
mediated noncytolytic suppression of HIV-1.
Reduction of noncytolytic suppression by a histone deacetylase inhibitor
is independent of the amount of HIV-1 gene expression
HDAC inhibitors have been shown to augment HTLV-1 (Mosley
et al., 2006) and HIV-1 gene expression (El Kharroubi et al., 1998;
Kiernan et al., 1999). A potential explanation of our results was that
HIV-1 gene expression, in the presence of VPA, increases in the target
cells to a level that noncytolytic suppression could not suppress. We
investigated whether the reversal of noncytolytic suppression by VPA
was dependent on the level of HIV-1 gene expression. Heterologous
contact-mediated noncytolytic suppression assays were performed in
cultures with a 20-fold range in HIV-1 gene expression, as measured
Fig. 1. Valproic acid decreases CD8+ T-lymphocyte noncytolytic suppression. (A) Primary CD4+ T-lymphocytes or HVS-transformed CD8+ T-lymphocytes were cultured for 16 h in
the presence or absence of 1.0 mM valproic acid. Acetylated and total histone 3 was analyzed by western blot. (B) Valproic acid was titrated into an autologous contact-mediated
suppression assay with seronegative cells at a 1:1 E:T ratio (open squares) or a heterologous assay with JR-HVS CD8+ T-lymphocytes at a 2:1 E:T ratio (ﬁlled circles). HIV-1
replication in CD8+ T-lymphocytes co-cultures is shown as the percentage of replication when the HIV-1 infected CD4+ T-lymphocytes were cultured alone. 0.5 and 1.0 mM valproic
acid signiﬁcantly increased replication in the JR-HVS CD8+ T-lymphocyte co-cultures (one-way ANOVA and Tukey test, pb0.05 and pb0.001, respectively). Valproic acid had no
effect on replication in the seronegative CD8+ T-lymphocyte co-cultures (one-way ANOVA and Tukey test, p=0.1177). Mean and standard error of 4 experiments are shown. (C)
Heterologous contact-mediated noncytolytic suppression assays were performed at multiple effector to target ratios in the absence (open circles) or presence of 1.0 mM valproic
acid (ﬁlled circles). HIV-1 replication in cultures containing CD8+ T-lymphocytes is shown as the percentage of replication when the HIV-1 infected CD4+ T-lymphocytes were
cultured alone. The effector to target ratio where 50% suppression (EC50) was reached was calculated for suppression assays done in the presence and absence of valproic acid.
Valproic acid signiﬁcantly increased replication in CD8+ T cell co-cultures at all three effector to target ratios (two-way ANOVA and Bonferoni corrected t-tests, p=0.0002). Mean
and standard error of 3 experiments are shown. (D) HIV-1 infected CD4+ T-lymphocytes were cultured alone or in a 0.4 μM transwell with JR-HVS CD8+ T cells at a 2:1 effector to
target ratio. Valproic acid was added in increasing concentrations to the transwell. HIV-1 replication in CD8+ T-lymphocytes co-cultures is shown as the percentage of replication
when the HIV-1 infected CD4+ T-lymphocytes were cultured alone. Signiﬁcant increases in replication were observed at 0.75 and 1.25 mM valproic acid concentrations (one-way
ANOVA and Tukey Test, pb0.05 for both). Mean and standard error of duplicate experiments are shown.
236 K.O. Saunders et al. / Virology 405 (2010) 234–242by LTR-driven luciferase expression, approaching the lower limit of
detection (1.6E6 to 0.08E6 relative light units). In the absence of the
HDAC inhibitor, there was no difference in suppression of the
infection in the CD8+ T-lymphocyte co-cultures at the different levels
of HIV-1 gene expression (Fig. 2). JR-HVS CD8+ T-lymphocytes
suppressed virus between 13.6% and 15.7% of the replication control
at a 2:1 E:T ratio across the different amounts of HIV-1 gene
expression. These results demonstrate that there is consistent
noncytolytic suppression of HIV-1 infection, despite the amount of
replication present. With histone deacetylation inhibited, noncytoly-
tic suppression was alleviated in a VPA dose-dependent manner
across the range of HIV-1 gene expression (Fig. 2). This reversion was
equivalent across all amounts of HIV-1 gene expression. Thus, at a
range of HIV-1 gene expression levels, inducing hyperacetylation of
histones can reverse noncytolytic CD8+ T cell mediated suppression.Primary CD8+ T-lymphocytes from HIV-1+ virus controllers optimally
suppress HIV-1 replication with a requirement for histone deacetylation
To extend the investigation to examine the impact of histone
deacetylation on in vivo control of HIV-1 infection, T-lymphocytes
from ﬁve HIV-1 infected subjects, naturally controlling HIV infection,
were examined in autologous noncytolytic suppression assays. HIV-1
infected CD4+ T-lymphocytes from virus controllers were cultured in
direct contact with autologous CD8+ T-lymphocytes at a 2:1 (E:T)
ratio. CD8+ T-lymphocytes from virus controllers were able to inhibit
virus replication signiﬁcantly better than cells from seronegative
donors (Fig. 3, pb0.001). CD8+ T-lymphocytes from HIV-1+ virus
controllers suppressed virus to a mean of 20.9% of the replication
control (Fig. 3). Inhibition of histone deacetylation, by valproic acid
stimulation (1.0 mM), signiﬁcantly reversed noncytolytic suppression
Fig. 2. Valproic acid inhibits CD8+ T-lymphocyte noncytolytic suppression at different
levels of HIV-1 gene expression. CD4+ T-lymphocytes were infected with four different
amounts of HIV-1NL4-3 pseudotyped virus to generate a titration of HIV-1 replication
from 1.6×106 to 0.08×106 relative light units. JR-HVS CD8+ T-lymphocytes were
cultured in direct contact at a 2:1 effector to target ratio with CD4+ T-lymphocytes
infected with each of the different amounts of HIV-1NL4-3 pseudotyped virus. Valproic
acid was added to the growth media in increasing concentrations. HIV-1 replication in
the CD8+ T-lymphocyte co-culture is shown as the percentage of replication in the
infected CD4+ T cells cultured alone. Mean and standard error of duplicate experiments
are shown.
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(p=0.01), but had no signiﬁcant effect on virus replication in the
presence of CD8+ T-lymphocytes from seronegative subjects (Fig. 3,
p=0.2). Valproic acid treatment reversed suppression by CD8+ T-
lymphocytes from HIV-1+ virus controllers such that the amount of
virus replication rose to the level of that observed in the presence of
the negative control CD8+ T cell lymphocytes from seronegativeFig. 3. Valproic acid inhibits contact-mediated CD8+ T-lymphocyte noncytolytic
suppression in virus controllers. HIV-1-infected primary CD4+ T-lymphocytes were
cultured in direct contact with or without autologous CD8+ T-lymphocytes at a 2:1
effector to target ratio. CD8+ T-lymphocytes from virus controllers (VC, circles) or
seronegative donors (SD, triangles) were examined. Noncytolytic suppression was
examined in the absence and presence of valproic acid (ﬁlled and open symbols,
respectively). Virus controller CD8 T cell co-cultures without valproic acid had
signiﬁcantly lower HIV-1 replication than seronegative CD8+ T cell co-cultures without
andwith valproic acid (unpaired t-test, p=0.0004 and p=0.0005). HIV-1 replication in
the virus controller CD8+ T-lymphocyte co-cultures signiﬁcantly increased with the
addition of valproic acid (paired t-test, p=0.0121). There was not a signiﬁcant increase
in replication in the seronegative CD8+ T-lymphocyte co-cultures (paired t-test,
p=0.2187). Means and standard error are represented by horizontal and vertical lines
respectively.donors. Inhibition of histone deacetylation signiﬁcantly reduced the
ability of CD8+ T-lymphocytes from HIV-1+ virus controllers to
suppress HIV-1 replication (pb0.001). The absolute level of respon-
siveness to the histone deacetylase inhibitor was heterogeneous
among the HIV-1+ virus controllers, consistent with the hypothesis
that multiple mediators at varying concentrations contribute to CD8+
mediated virus suppression. However, some CD8+ T-lymphocytes
from HIV-1+ virus controllers have nearly identical responsiveness to
the HDAC inhibitor as the CD8+ T cell effector cell line (Figs. 1B and 3).
In total, inhibition of HDACs prevented optimal noncytolytic sup-
pression of HIV-1 by CD8+ T-lymphocytes from HIV-1+ virus
controllers, which recapitulated the effects of valproic acid observed
with the CD8+ T cell effector cell line.
Histone deacetylase 1 in HIV-1 infected target cells is not required for
CD8+ T-lymphocyte noncytolytic suppression of HIV-1
To determine if CD8+ T-lymphocytes induce HDAC1 in HIV-1
infected CD4+ target cells to inhibit HIV-1 transcription, we used RNA
interference to deplete target cells of HDAC1. We used a pool of
siRNAs targeting HDAC1 to knockdown expression in infected target
cells. HDAC1 siRNA transfected cells were substantially depleted of
HDAC1, when compared to mock or negative control siRNA
transfected cells (Fig. 4A) and HDAC1 remained knocked-down
throughout the suppression assay (96 h post transfection). HDAC1-
expressing and deﬁcient cells were used in soluble noncytolytic
suppression assays with CD8+ T-lymphocytes from a seronegative
donor, CD8+ T-lymphocytes from an HIV-1+ virus controller (VC18),
or the JR-HVS cell line. As expected, the seronegative donor CD8+ T-
lymphocytes showed the least suppressive capability overall and
there was no effect on HIV replication when HDAC1 was knocked-
down (Fig. 4B). Also as expected, both primary CD8+ T-lymphocytes
from a virus controller (VC18) and JR-HVS CD8+ T-lymphocytes
substantially inhibited virus replication (Figs. 4C and D). However,
there was also no change in the suppressive activity when HDAC1was
knocked-down (Figs. 4C and D). HIV-1 replication decreased with
each increase in effector to target ratio to similar levels despite the
differences in HDAC1 protein expression. Thus, the presence of
HDAC1 in HIV-1 infected CD4+ target cells was not necessary for
noncytolytic suppression of HIV-1 replication. Taken together, these
data demonstrate that HDAC1 in the CD4+ target cells was not
responsible for the requirement of histone deacetylation for optimal
noncytolytic suppression.
Histone acetylation at the HIV-1 LTR in CD4+ target cells is unchanged
by noncytolytic suppression
The results of the RNA interference experiments demonstrated
that HDAC1 in the infected target cells was not mediating the
suppression of HIV-1 transcription during noncytolytic suppression.
However, recent data suggests that other HDACs may regulate HIV-1
gene expression (Archin et al., 2009), and thus could deacetylate
histones in the absence of HDAC1. Thus, we examined changes in the
acetylation state of the histones within the HIV-1 LTR during
noncytolytic suppression. A large-scale noncytolytic suppression
assay was performed, and native chromatin was isolated from these
cultures. JR-HVS CD8+ T-lymphocytes strongly inhibited HIV-1
replication, but seronegative CD8+ T-lymphocytes did not
(Fig. 5A). However, there was no signiﬁcant decrease in acetylated
histones associated with the HIV-1 LTR during noncytolytic sup-
pression, despite potent suppression of HIV-1 replication (Fig. 5B). In
the absence of CD8+ T-lymphocytes, 1.5% of the HIV-1 LTR was
associated with H3ac in the absence of any CD8+ T-lymphocytes.
This was very similar to the 1.4% of the LTR associated with
acetylated histone 3 in infected cells cultured with seronegative
CD8+ T-lymphocytes and the 1.6% in infected cells cultured with JR-
Fig. 4. HDAC1 is not required for soluble CD8+ T-lymphocyte noncytolytic suppression. (A) siRNA-mediated knockdown of histone deacetylase 1. TZM-bl cells were transfected with
no (Mock), a negative control (Negative) or HDAC1-speciﬁc (HDAC1) siRNAs. 48 and 96 h post transfection cells were lysed and HDAC1 and β-actin expression was determined by
western blot. (B–D) Soluble noncytolytic suppression of HDAC1-deﬁcient TZM-bl cells. TZM-bl cells expressing HDAC1 (mock; ﬁlled circles or Negative control; open square) or with
HDAC1 knocked-down (HDAC1; ﬁlled triangle) were used as targets for soluble noncytolytic suppression assays. (B) Seronegative, (C) virus controller 18 (VC18), or (D) JR-HVS CD8+
T-lymphocytes were cultured in a transwell system with HIV-1IIIB infected TZM-bl cells at various effector to target ratios. 48 h after infection LTR-driven luciferase expression was
quantiﬁed. HIV-1 replication in the culture in the presence of the CD8+ T-lymphocytes is shown as a percentage of the replication control. Mean and standard error of 3 experiments
are shown.
Fig. 5. CD8+ T-lymphocyte noncytolytic suppression does not alter the acetylation of histone 3 at the HIV-1 LTR. (A) CD4+ T-lymphocytes were infected with replication-competent
HIV-1IIIB and cultured alone (ﬁlled bars) or in the presence of seronegative (open bars) or JR-HVS (gray bars) CD8+ T-lymphocytes. HIV-1 replication was determined by virion-
associated reverse transcriptase activity in the culture supernatant 6 days post-infection. Percent of the replication control was calculated with the samemethod as luciferase assays,
Mean and standard error of 3 experiments are shown. (B) Native chromatin was puriﬁed from the noncytolytic suppression assays in (A). Acetylated histone 3 associated with the
HIV-1 LTR (open bars) or a housekeeping gene (GAPDH; ﬁlled bars) was detected by quantitative native chromatin immunoprecipitation. The copies of DNA coimmunoprecipitated
with acetylated histone 3 is shown as a percentage of the total DNA used for the immunoprecipitation input. Mean and standard error of 3 experiments are shown.
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239K.O. Saunders et al. / Virology 405 (2010) 234–242HVS CD8+ T-lymphocytes. As a control for changes in histone
acetylation at the promoter of host genes, association of GAPDH DNA
with H3ac was determined. There was no difference in enrichment of
H3ac with GAPDH DNA in any of the three conditions (Fig. 5B).
Alterations of the acetylation state of histones at the viral promoter
did not mediate noncytolytic suppression; and could not explain the
requirement for histone deacetylases for noncytolytic suppression.Inhibition of histone deacetylases in primary CD8+ T-lymphocytes from
HIV-1+ subjects decreases their noncytolytic suppressive activity
Since the requirement for histone deacetylation in suppression of
HIV-1 replication was not localized to the infected target cells, we
determined whether histone deacetylation directly regulated the
suppressive capacity of the CD8+ T-lymphocytes. We found that CD8+
effector lymphocytes and cell lines were resilient to attempts to
knockdown HDAC, so we utilized another effective strategy of
interrogating the contribution of HDAC regulation in CD8+ effector
cells using valproic acid treatment. JR-HVS CD8+ T-lymphocytes were
incubated with valproic acid for 16 hours and subsequently used as
effector cells in a noncytolytic suppression assay. Noncytolytic suppres-
sion decreased incrementally with increasing concentrations of valproic
acid pretreatment; with suppression being almost completely elimi-
nated with 2 mM valproic acid treatment (Fig. 6A). Therefore, the
shorter exposure time, 16 h instead of 72 h, appeared to warrant a
higher concentration of valproic acid to exhibit the most potent effects.
Suppressive activity mediated by CD8+ T-lymphocytes from either the
HIV-1+virus controller (VC6) or JR-HVS CD8+ T-lymphocytes declined
in a dose-dependent manner when the CD8+ T-lymphocytes were
pretreated with valproic acid (Fig. 6A).
To determine how common the dependence on histone deacetyla-
tion is for CD8+ T-lymphocytes from HIV-1+ virus controllers, we
went on to further examine CD8+ T-lymphocytes from 13 different
subjects. Inhibiting histone deacetylation by pretreatment withFig. 6. Incubation of CD8+ T-lymphocytes in valproic acid inhibits their noncytolytic suppres
different concentrations of valproic acid for 16 h and subsequently cultured with HIV-1NL4-
Incubation of primary CD8+ T-lymphocytes from virus controllers in valproic acid has va
controllers (squares) or seronegative donors (triangles) were treated with 2.0 mM valp
heterologous HIV-1-infected CD4+ T-lymphocytes at a 0.5:1 effector to target ratio. HIV-1
replication control. HIV-1 replication was signiﬁcantly lower in the presence of virus contro
test, pb0.0001). Valproic acid signiﬁcantly increased replication in the virus controller CD
increase in replication in the co-cultures containing valproic acid-treated seronegative CD8+
horizontal and vertical lines respectively.valproic acid signiﬁcantly decreased noncytolytic suppression across
the panel of CD8+ T-lymphocytes from 13 virus controllers to varying
degrees (p=0.0003, Fig. 6B). In contrast, valproic acid treatment did
not signiﬁcantly alter HIV-1 replication in the presence of seroneg-
ative CD8+ T-lymphocyte from eight different subjects (b6% change,
p=0.2) (Fig. 6B). For one virus controller, CD8+ T-lymphocytes
substantially suppressed virus replication to 8.8% of the replication
control, but was increased to 43.1% of the replication control by
valproic acid treatment (Fig. 6B). Virus replication in cultures
containing valproic acid-treated CD8+ T-lymphocytes from a second
virus controller increased up to 35.1% of the replication control
(Fig. 6B). In the case of another virus controller, virus replication
increased from 4% to 25% with valproic acid-treated CD8+ T-
lymphocytes. Inhibition of HDACs in the CD8+ T-lymphocytes
reduced suppression by more than 20% in 5 of the 13 virus controllers
tested. Valproic acid pretreatment of CD8+ T-lymphocytes from VC3
reversed suppression by 11%, identical to the change seen when
valproic acid was present during co-culture (Figs. 3 and 6B). Thus,
valproic acid pretreatment of CD8+ T-lymphocytes from both virus
controller 3 and 6 with valproic acid produced similar results to those
seen when valproic acid was added during the co-culture. None of the
virus controllers suppressed HIV-1 better after valproic acid pretreat-
ment. Inhibition of HDACs in primary CD8+ T-lymphocytes from HIV-
1+ virus controllers and the CD8+ effector cell line impaired their
suppressive responses. In summary, this study demonstrates that
chromatin modiﬁcations through histone deacetylation within effec-
tor CD8+ T-lymphocytes can be required for optimal CD8+ T-
lymphocyte noncytolytic suppression of HIV-1.Discussion and conclusions
Understanding the regulation of the CD8+ T cell mediated
noncytolytic response has been an elusive goal since its discovery
more than 20 years ago. We detail here the ﬁrst evidence that thesive activity. (A) Virus controller 6 and JR-HVS CD8+ T-lymphocytes were incubated in
3 pseudotyped virus-infected CD4+ T-lymphocytes at a 2:1 effector to target ratio. (B)
ried effects on their suppressive activity. Panels of CD8+ T-lymphocytes from virus
roic acid (VPA) as in (A). The pretreated CD8+ T-lymphocytes were cultured with
replication in the CD8+ T-lymphocyte co-culture is shown as the percentage of the
ller CD8+ T-lymphocytes compared to seronegative CD8+ T-lymphocytes (unpaired t-
8+ T-lymphocyte co-cultures (paired t-test, p=0.0003). There was not a signiﬁcant
T-lymphocytes (paired t-test, p=0.2076). Means and standard error are represented by
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histone deacetylation. Our data suggests that histone hyperacetyla-
tion induces expression of negative regulators of the antiviral factors,
which leads to diminished noncytolytic suppression. Studies of the
cytolytic response have shown that HDAC inhibitors augment the
cytolytic response by CD8+ T-lymphocytes (Agarwal et al., 2009).
Exposing CD8+ T-lymphocytes to a HDAC inhibitor during antigen
stimulation increased speciﬁc killing, and secretion of gamma
interferon, MIP-1 alpha and MIP-1 beta (Agarwal et al., 2009).
Conversely, our data suggests that histone hyperacetylation decreases
noncytolytic suppression of HIV-1. These data further distinguish the
cytolytic and noncytolytic responses in CD8+ T-lymphocytes, and
indicate distinct networks of genes that mediate each response. The
varied responses seen with virus controller CD8+ T-lymphocytes
suggests that the network of genes may be heterogeneous and that
the totality of genes that can comprise the noncytolytic response may
not be common among all HIV-1 infected individuals. Therefore,
inhibiting HDACs may lead to different degrees of impact on virus
suppression among individuals. The heterogeneous nature of the
noncytolytic response has been speculated since some HIV-infected
individuals exhibit contact-mediated suppression, but not soluble
noncytolytic suppression (Walker and Levy, 1989). The presence of
multiple mediators was also shown by size chromatography of CD8+
T-lymphocyte supernatants. In these experiments partial suppressive
capacity was found in fractions of different sizes, and the sum of the
suppression by each fraction totaled the suppression of the unfractio-
nated supernatant (Geiben-Lynn et al., 2001). We propose that the
noncytolytic response is a combination of several factors, with at least
a subset of these factors being directly or indirectly regulated by
changes in chromatin structure.
The mechanism of HIV-1 transcriptional inhibition is still unclear.
HIV-1 proviral latency is maintained by histone deacetylases that
inhibit transcription from the HIV-1 LTR (Tyagi and Karn, 2007;
Williams et al., 2006; Ylisastigui et al., 2004). We show here that
noncytolytic suppression does not block HIV-1 transcription initiation
with similar mechanisms. HDAC1 is thought to be a mediator of HIV-1
proviral latency, but was dispensable for noncytolytic suppression of
HIV-1 infected TZM-bl cells. Mosoian and colleagues have demon-
strated that mediators of noncytolytic suppression differ in macro-
phages and T cells (Mosoian et al., 2006); thus, the requirement of
HDAC1 in other cell types warrants further examination. HDAC1
decreases the acetylation of histones, an effect that we did not observe
at the HIV-1 LTR in the presence of noncytolytic suppression of T-
lymphocytes. Therefore, noncytolytic suppression inhibits HIV-1
transcription in acute infection in a manner different from what has
been proposed for proviral latency.
In our study we saw impairment of the noncytolytic response at
concentrations of valproic acid previously reported to be found in the
blood of treated subjects (Gottlicher et al., 2001; Jennings and
Romanelli, 1999). At these concentrations, valproic acid has no effect
on apoptosis or the cell cycle (Gottlicher et al., 2001). Mosley et al.
have found that valproic acid becomes toxic to CD8+ T-lymphocytes,
impairing their cytolytic activity at levels 2.5 times the highest
concentrations used in our study (Mosley et al., 2006). Similarly, we
found Trichostatin A to be toxic at nanomolar concentrations to T-
lymphocytes in our hands, which led us to use valproic acid in this
study. However, Trichostatin A has been shown to enhance T-
lymphocyte differentiation into memory T-lymphocytes capable of
lysis of target cells (Agarwal et al., 2009; Northrop et al., 2008).
Clearly, the amount and type of HDAC inhibitor has to be considered
carefully when designing in vitro studies; and CD8+ T cell responses
need to be examined more closely in HIV-1 infected patients treated
with HDAC inhibitors.
The multifactorial, heterogeneous nature of the antiviral response
makes antibody blocking of single molecules unproductive, and
demonstrates the necessity for multigene approaches to identify themediators and mechanisms of noncytolytic suppression. Microarray
studies have shown that histone deacetylases regulate the expression
of 8.7% of the genes analyzed in human CD8+ T-lymphocytes
(Agarwal et al., 2009). A portion of the noncytolytic suppressive
factors are likely contained within this subset of genes, since histone
hyperacetylation down-modulates noncytolytic suppression. Micro-
array analysis of CD8+ T-lymphocytes with and without noncytolytic
suppression has been complicated by determining relevant differ-
ences in CD8+ T-lymphocytes from different donors with different
genetic backgrounds. Histone deacetylase inhibitors can be used to
down-modulate noncytolytic suppression, allowing comparative
genetic analyses of the same cells with and without noncytolytic
suppressive activity. Future studies should aim to identify potential
suppressive factors by analyzing the changes in mRNA or protein
levels of secreted molecules from untreated or valproic acid-treated
CD8+ T-lymphocytes. The availability of multiplex bead-based assays
and quantitative PCR has made it increasingly easier to deﬁne
expression proﬁles of speciﬁc cells. These technologies coupled with
histone deacetylase inhibitors provide a more focused approach for
identifying some of the novel antiviral molecules secreted by CD8+ T-
lymphocytes.
Materials and methods
Study participants
HIV-1+ subjects controlling virus replication (virus controllers)
with CD4+ T cell counts greater than 385 cells/μL and a viral load less
than 5000 copies/mL were recruited from the Duke Adult and
Pediatric Infectious Disease Clinics. Informed consent was obtained
from all study participants according to a Duke University IRB
approved protocol. Seronegative PBMCs were isolated from blood
donors from the Red Cross.
Cell culture
PBMCs from seronegative donors or virus controllers were
activated for 3 days with anti-CD3 and anti-CD28 in RPMI (20% FBS,
1% Penicillin–Streptomycin, 20 U/mL IL-2). CD4+-enriched cells were
obtained from activated PBMCs by negative selection using anti-CD8
immunomagnetic beads (Invitrogen). CD8+-enriched cells were
obtained similarly with anti-CD4 immunomagnetic beads (Invitro-
gen) or with the CD8+ T Cell Isolation kit and an autoMACS Cell
Separator per the manufacturer's procedure (Miltenyi Biotechnolo-
gy). CD4+ and CD8+ T-lymphocyte purity was routinely 94% and 93%,
respectively. The HVS-transformed CD8+ T-lymphocyte cell line from
an asymptomatic HIV-1 infected subject, JR-HVS (Lacey et al., 1998),
was cultured in AIM-V (20% FBS, 40 U/mL IL-2). TZM-bl cells were
cultured in DMEM (10% FBS, 1% Penicillin–Streptomycin).
Acute HIV-1 CD8+ T-lymphocyte suppression assays
In autologous assays, CD4+-enriched cells were infected with a
single cycle HIV-1NL4-3 pseudotyped luciferase reporter virus for 2 h in
a 50 mL conical tube (Overman et al., 2007). This pseudotyped virus
contains the NL4-3 genome encoding luciferase in the place of nef.
Envelope production by this virus is abrogated by a frameshift
mutation, limiting virus replication to one cycle. (Connor et al., 1995).
HIV-1 infected CD4+ cells were plated with autologous CD8+ T cells
or cultured alone. PBS or valproic acid (Calbiochem) dissolved in PBS
was added to HIV-1 infected CD4+-enriched cells growing alone (HIV
replication control) or together with autologous CD8+ T cells (CD8+ T
cell co-culture). At 72 h post-infection, the cells were lysed with
Luciferase Cell Culture Lysis reagent (Promega) and one freeze–thaw
cycle. Luciferase expression was quantiﬁed with the Luciferase Assay
System (Promega) on a Centro LB luminometer (Berthold). The level
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infected CD4+ T cells was expressed as the percent of the HIV
replication in CD4+ T-lymphocytes alone : [relative light units
(luciferase) in the co-culture of CD8+ and infected CD4+ T-
lymphocytes (CD8+ T cell co-culture)]/[relative light units (lucifer-
ase) in infected CD4+ T cells alone (replication control)]×100%. CD8+
T cell co-cultures containing valproic acid were compared to
replication control wells with the same treatment to control for
effects of VPA on HIV-1 replication.
Heterologous assays were performed similarly. CD4+-enriched
cells were obtained from activated PBMCs from a pool of 10
seronegative donors. Infections and valproic acid treatment were
performed as described above. HVS-transformed CD8+ T cells from an
asymptomatic HIV-infected individual known to demonstrate potent
noncytolytic suppression were added to the culture to assess the
mechanisms of noncytolytic suppression. To distinguish soluble
suppression, infected CD4+ T cells were plated in the lower chamber
of a 96-well 0.4 μM Pore Transwell system (Corning) and CD8+ T cells
were added to the upper chamber.
Valproic acid pretreatment assay
CD8+ T cells were cultured in media containing PBS or valproic
acid dissolved in PBS for 16 h. The CD8+ T cells were subsequently
washed, counted, and plated in a contact-mediated noncytolytic
suppression assay as stated above. Viability of the CD8+ T cells after
pretreatment was above 90% as determined by Guava VIACount
assays (Millipore) per themanufacturer's protocol at the conclusion of
the assay.
Western blot
Cells were lysed in RIPA buffer (0.1% SDS, 0.1% NP-40, 0.5% Sodium
deoxycholate) and protein concentration was determined with the
QuickStart Bradford Assay (Bio-Rad). Thirty μg of TZM-bl, 30 μg of CD4+
T-lymphocytes or 60 μg of CD8+ T-lymphocytes protein was fraction-
ated by 7.5% SDS-PAGE. Proteinwas transferred to PVDFmembrane and
blocked with 5% BLOTTO. Membranes were probed with a 1:5000
dilution of primary antibody and a 1:10,000 dilution of anti-rabbit
antibody (GE Healthcare). Total histone 3 was detected with anti-
histone 3 clone ab8898 (Abcam). Acetylated histone 3 was detected
with antibody clone 06-599 (Millipore). Blots were detected with
autoradiography using an ECL Plus Kit (GE Healthcare).
Soluble noncytolytic suppression of HDAC1-deﬁcient cells
siRNA-mediated knockdown of HDAC1
TZM-bl cells were plated at 80,000 cells per well in a 12-well plate
in DMEM 24 h before transfection. DharmaFect1 (Dharmacon) was
used to transfect siRNAs per the manufacturer's protocol. To
knockdown HDAC1 expression, SMARTpool HDAC1 siRNAs (Dharma-
con) were used. Negative Control siRNA 1 (Ambion) was used a
negative control. Nuclease-free water was used in the place of siRNAs
for mock transfections. TZM-bl cells were transfected with a ﬁnal
concentration of 200 nM of siRNA. Efﬁcient knockdown was assessed
by western blot using anti-HDAC1 clone 7028 (Abcam) and anti-β-
actin clone 8227 (Abcam).
Soluble noncytolytic suppression assay
Forty-eight hours post transfection, TZM-bl cells were trypsinized
and washed once with complete growth media. TZM-bl cells were
plated at 16,000 cells per well in the lower chamber of a 96-well
0.4 μM Pore Transwell system (Corning) and were infected with the
CXCR4-tropic virus, HIV-1IIIB, at anMOI of 0.5. Activated primary or JR-
HVS CD8+ T-lymphocytes were plated in the upper chamber of the
transwell system at various effector to target ratios at the time ofinfection of the target cells. LTR-driven luciferase expression was
measured using the BriteLite Plus system (Perkin Elmer) at 48 h post-
infection (96 h post transfection). Viability (N92%) of the TZM-bl cells
was determined using the Guava VIACount assay (Millipore) per the
manufacturer's protocol at the conclusion of the assay. The remaining
transfected TZM-bl cells were analyzed for HDAC1 expression by
Western blot at the initiation and at the completion of the assay.Quantitative native chromatin immunoprecipitation of acetylated
histone 3 (H3ac)
Native chromatin puriﬁcation
Large-scale contact-mediated noncytolytic suppression assays
were performed with HIV-1IIIB at a multiplicity of infection of
0.0075. Virion-associated reverse transcriptase activity in the culture
supernatant was used to determine virus replication at 3 and 6 days
post-infection as described elsewhere (Miller et al., 2009). Native
chromatin was puriﬁed as previously described (Blower et al., 2002)
with the following modiﬁcations: Cells from contact-mediated
noncytolytic suppression assays were pelleted and resuspended in
Chromatin Isolation Buffer (CIB) supplemented with Complete Mini
Protease inhibitors (Roche) and NP-40 to 0.5%. Cells were broken on
ice with 45 strokes of a Dounce homogenizer. Nuclei were washed
once with CIB and resuspended in CIB supplemented with 1 mM
CaCl2. Micrococcal nuclease was used to digest the chromatin. Nuclei
were pelleted at 1000×g for 6 min and incubated on ice for 2 h in
500 mM NaCl in PBS. Insoluble chromatin was pelleted at 20,000×g
for 15 min, the supernatant was retained as the soluble native
chromatin.Chromatin immunoprecipitation (ChIP)
ChIPwas performed as previously described (Mravinac et al., 2009)
except 55 μg of chromatinwas used. Four μg of anti-acetylatedHistone
3 [clone 06-599 (Millipore)] was used for immunoprecipitation. A
mock immunoprecipitation containing no antibody was performed as
a negative control. HIV-1 LTR DNA was detected with real-time PCR
using Power SYBR Green PCR master mix (Applied Biosystems) and
the following HIV-1-speciﬁc primers: HIV-1 5′ LTR forward: 5′-
GCCTGGGAGCTCTCTGGCTA-3′; HIV-1 5′ LTR reverse: 5′-CAACA-
GACGGGCACACACTACTT-3′. As a control, GAPDH DNA was detected
with GAPDH promoter primers that have been detailed elsewhere
(Spilianakis et al., 2003). ChIP results were analyzed as percent of the
total input used for immunoprecipitation. Percent of the total input
was calculated using the following formula: (copies immunoprecipi-
tated with anti-acetylated Histone 3−copies immunoprecipitated
with no antibody)/([copies in the 10% input×10]−copies immuno-
precipitated with no antibody)×100%.Acknowledgments
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